In This Article:
Croda International (LON:CRDA) Full Year 2024 Results
Key Financial Results
-
Revenue: UK£1.63b (down 3.9% from FY 2023).
-
Net income: UK£158.5m (down 7.3% from FY 2023).
-
Profit margin: 9.7% (in line with FY 2023).
-
EPS: UK£1.14 (down from UK£1.23 in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Croda International EPS Misses Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 6.7%.
The primary driver behind last 12 months revenue was the Consumer Care segment contributing a total revenue of UK£920.0m (57% of total revenue). Notably, cost of sales worth UK£894.2m amounted to 55% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to UK£422.8m (73% of total expenses). Explore how CRDA's revenue and expenses shape its earnings.
Looking ahead, revenue is forecast to grow 5.6% p.a. on average during the next 3 years, compared to a 3.9% decline forecast for the Chemicals industry in the United Kingdom.
Performance of the British Chemicals industry.
The company's shares are down 4.5% from a week ago.
Risk Analysis
Before we wrap up, we've discovered 1 warning sign for Croda International that you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.